Richman Douglas D
University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus); Director, The HIV Institute; Co- Director, San Diego Center for AIDS Research; Florence Seeley Riford Emeritus Chair in AIDS Research, CA, USA.
Glob Health Med. 2021 Feb 28;3(1):1-5. doi: 10.35772/ghm.2021.01010.
The speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding ) considerations of the rollout and implementation of the multiple vaccines, ) the use of the vaccines in ways different from those used in the registrational phase 3 studies, ) the future both of SARS-CoV-2 in the human population and of "normal" human life returning after widespread vaccination, and ) the implications of the success of these SARS-CoV-2 vaccines for vaccine development against other pathogens.
最近研发的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗，其研发速度和功效程度着实令人瞩目。本社论不会总结这些疫苗的设计和临床试验结果等已被广泛宣传和审查的信息。相反，我将推测几个问题，包括：一、多种疫苗推广和实施的考量；二、疫苗使用方式与注册3期研究中的使用方式的不同之处；三、SARS-CoV-2在人群中的未来以及广泛接种疫苗后“正常”人类生活的回归；四、这些SARS-CoV-2疫苗的成功对针对其他病原体的疫苗研发的影响。
